资源类型：
期刊
WOS体系：
Correction
Pubmed体系：
Journal Article;Published Erratum
收录情况：
◇ SCIE
文章类型：
修订
机构：
[a]Department of Rheumatology, The First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, China
内科片
风湿免疫科
云南省第一人民医院
[b]Department of Orthopedics, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China
昆明医科大学附属第一医院
ISSN：
0753-3322
摘要：
[Figure presented] The authors regret that the picture of the U2OS inhibitor NC group in Fig. 3D was mistaken and has to be replaced with a correct one. Please be noted that the figure legend for Fig. 3D are correct, and the conclusions made in the paper are not influenced. The authors would like to apologise for any inconvenience caused. © 2020 Elsevier Masson SAS
WOS：
WOS:000561740000009
PubmedID：
32475632
中科院(CAS)分区：
出版当年[2020]版：
大类
|
2 区
医学
小类
|
2 区
药学
3 区
医学：研究与实验
最新[2025]版：
大类
|
2 区
医学
小类
|
2 区
医学：研究与实验
2 区
药学
JCR分区：
出版当年[2019]版：
Q1
PHARMACOLOGY & PHARMACY
Q1
MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Q1
PHARMACOLOGY & PHARMACY
影响因子：
6.9
最新[2023版]
6.8
最新五年平均
4.545
出版当年[2019版]
4.392
出版当年五年平均
3.743
出版前一年[2018版]
6.53
出版后一年[2020版]
第一作者：
Wang, J
第一作者机构：
[a]Department of Rheumatology, The First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, China
通讯作者：
Chen, L.-Q
推荐引用方式(GB/T 7714)：
Wang J,Wang B,Chen L.-Q,et al.Corrigendum to “miR-10b promotes invasion by targeting KLF4 in osteosarcoma cells” [Biomed. Pharmacother. 84 (2016) 947–953] (Biomedicine & Pharmacotherapy (2016) 84 (947–953), (S0753332216316596), (10.1016/j.biopha.2016.09.108))
(Open Access)[J].BIOMEDICINE & PHARMACOTHERAPY.2020,128:doi:10.1016/j.biopha.2020.110175.
APA：
Wang, J,Wang, B,Chen, L.-Q,Yang, J,Gong, Z.-Q...&Du, K.-L.(2020).Corrigendum to “miR-10b promotes invasion by targeting KLF4 in osteosarcoma cells” [Biomed. Pharmacother. 84 (2016) 947–953] (Biomedicine & Pharmacotherapy (2016) 84 (947–953), (S0753332216316596), (10.1016/j.biopha.2016.09.108))
(Open Access).BIOMEDICINE & PHARMACOTHERAPY,128,
MLA：
Wang, J,et al."Corrigendum to “miR-10b promotes invasion by targeting KLF4 in osteosarcoma cells” [Biomed. Pharmacother. 84 (2016) 947–953] (Biomedicine & Pharmacotherapy (2016) 84 (947–953), (S0753332216316596), (10.1016/j.biopha.2016.09.108))
(Open Access)".BIOMEDICINE & PHARMACOTHERAPY 128.(2020)
